<DOC>
	<DOCNO>NCT02205437</DOCNO>
	<brief_summary>Schizophrenia severe chronic mental disorder . The lifetime risk schizophrenia around 1 % . Its course chronic frequently disable . The keystone schizophrenia treatment antipsychotic medication . The use antipsychotics represent huge public health economic burden society . Most antipsychotic drug `` metoo '' drug , directly indirectly replicate dopamine D2 receptor blockade . Pharmaceutical company aim produce drug general indication patient schizophrenia `` one-size-fits-all '' strategy target stratification . Second generation antipsychotic partly improve positive symptom quite often associate weight gain , metabolic change increase risk cardiovascular disease . Antipsychotics achieve certain degree clinical improvement percentage patient ( 45 % ) 30 % patient treatment resistant . In light current deadlock , urgent need expand horizon pharmacological research elucidate new mechanism relate antipsychotic action . An alternative strategy comparison gene expression profile drug-naive accurately ill patient antipsychotic treatment initiate . Our research group great experience field work hypothesis late year . We propose continuation project thoroughly explore clinical implication ( clinical response antipsychotic drug emergence metabolic side effect ) variant gene expression recently describe schizophrenia patient . This project take advantage exceptional ( regard detail knowledge clinical outcome side effect profile ) longitudinal cohort drug-naive patient schizophrenia follow three year University Hospital Marqu√©s de Valdecilla .</brief_summary>
	<brief_title>Novel Candidate Genes Treatment Response Antipsychotics Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Patients follow 3 year First Episode Psychosis Clinical Program ( PAFIP ) . 1560 year . Living catchment area . Experiencing first episode psychosis . No prior treatment antipsychotic medication , previously treat , total life time adequate antipsychotic treatment le 6 week . Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) criteria brief psychotic disorder , schizophreniform disorder , schizophrenia , schizoaffective disorder . Meeting DSMIV criterion drug dependence . Meeting DSMIV criterion mental retardation . Having history neurological disease head injury .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Psychosis</keyword>
	<keyword>Antipsychotics</keyword>
	<keyword>Treatment response</keyword>
	<keyword>Metabolic side effect</keyword>
	<keyword>Gene expression</keyword>
	<keyword>RNA</keyword>
	<keyword>Genes</keyword>
</DOC>